Chemoprevention of Urothelial Cell Carcinoma Tumorigenesis by Dietary Flavokawain A in UPII-Mutant Ha-ras Transgenic Mice
Open Access
- 24 February 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 496
Abstract
Non-muscle-invasive bladder cancer (NMIBC) has one of the highest recurrence rates among all solid cancers and the highest lifetime treatment cost per patient. Therefore, the development of chemoprevention strategies for reducing the occurrence and recurrence of NMIBC as well as its burdens on the healthcare system is valuable. Our aim was to determine whether flavokawain A (FKA), a kava chalcone isolated from the kava plant, can target the in vivo activated Ha-ras pathway for prevention and treatment of NMIBC. UPII-mutant Ha-ras transgenic mice that develop papillary urothelial cell carcinoma were fed orally with vehicle control or FKA-formulated food for 6 months starting at 6 weeks of age. Seventy-nine percent (15/19) of male mice fed with 6 g FKA per kilogram (kg) of food survived beyond the 6 months of treatment, while 31.6% (6/19) of control food-fed male mice survived the 6-month treatment period (p = 0.02). The mean bladder weights in FKA vs. control food-fed mice were 0.216 ± 0.033 vs. 0.342 ± 0.039 g in male mice (p = 0.0413) and 0.043 ± 0.004 vs. 0.073 ± 0.004 g in female mice (p < 0.0001); FKA reduced bladder weight by 37% and 41%, respectively. The tumor burdens, determined by the wet bladder weight, in these mice were inversely related to plasma FKA concentrations. In addition to decreased bladder weight, FKA treatment significantly reduced the incidences of hydronephrosis and hematuria. FKA-treated mice exhibited more well-differentiated tumors in the bladder and ureter. Immunohistochemical analysis of FKA-treated tumors compared to those in the control group revealed fewer Ki-67- and survivin-positive cells and an increased number of p27- and TUNEL-positive cells, indicating that FKA inhibits proliferation and induces apoptosis. Overall, the results suggest that FKA can target the in vivo activated Ha-ras pathway for the prevention and treatment of NMIBC.Keywords
Funding Information
- National Cancer Institute (5R01CA193967-05, 5R01CA122558-05)
This publication has 29 references indexed in Scilit:
- Biotransformation of Flavokawains A, B, and C, Chalcones from Kava (Piper methysticum), by Human Liver MicrosomesJournal of Agricultural and Food Chemistry, 2015
- Flavokawain A Induces Apoptosis in MCF-7 and MDA-MB231 and Inhibits the Metastatic Process In VitroPLOS ONE, 2014
- Dietary feeding of flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in miceToxicology Reports, 2014
- KAVA Chalcone, Flavokawain A, Inhibits Urothelial Tumorigenesis in the UPII-SV40T Transgenic Mouse ModelCancer Prevention Research, 2013
- Prognostic factors for upper urinary tract urothelial carcinomaNature Reviews Urology, 2011
- Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinomaThe Journal of Pathology, 2011
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- Effects of the Kava Chalcone Flavokawain A Differ in Bladder Cancer Cells with Wild-type versus Mutant p53Cancer Prevention Research, 2008
- Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesisJournal of Clinical Investigation, 2007
- Urothelial tumorigenesis: a tale of divergent pathwaysNature Reviews Cancer, 2005